

(a)



(b)

Figure S1. DSC thermograms of celecoxib, ModE copolymers, and the corresponding S-SNEDDS (a), celecoxib and other marketed (co)polymers used in the study, and the corresponding S-SNEDDS (b).



(a)



(b)

Figure S2. DSC thermograms of efavirenz, ModE copolymers, and the corresponding S-SNEDDS (a), efavirenz and other marketed (co)polymers used in the study, and the corresponding S-SNEDDS (b)



(a)



(b)

Figure S3. DSC thermograms of fenofibrate, ModE copolymers, and the corresponding S-SNEDDS (a), fenofibrate and other marketed (co)polymers used in the study, and the corresponding S-SNEDDS (b).



(a)



(b)

Figure S4. DSC thermograms (after six months of storage at 30 °C/65% RH) of celecoxib, ModE copolymers, and the corresponding S-SNEDDS (a), celecoxib and other marketed (co)polymers used in the study, and the corresponding S-SNEDDS (b).



(a)



(b)

Figure S5. DSC thermograms (after six months of storage at 30 °C/65% RH) of efavirenz, ModE copolymers, and the corresponding S-SNEDDS (a), efavirenz and other marketed (co)polymers used in the study, and the corresponding S-SNEDDS (b).



(a)



(b)

Figure S6. DSC thermograms (after six months of storage at 30 °C/65% RH) of fenofibrate, ModE copolymers, and the corresponding S-SNEDDS (a), fenofibrate and other marketed (co)polymers used in the study, and the corresponding S-SNEDDS (b).



(a)



(b)

Figure S7. Dissolution profiles of celecoxib drug substance and celecoxib L- and S-SNEDDS based on ModE (a), as well as celecoxib drug substance and celecoxib L- and S-SNEDDS based on other marketed (co)polymers (b) (after three months of storage at 30 °C/65% RH) in 500 mL 0.1 M HCl in USP apparatus II. Each value designates the mean ± S.D. (n = 3).



(a)



(b)

Figure S8. Dissolution profiles of efavirenz drug substance and efavirenz L- and S-SNEDDS based on ModE (a), as well as efavirenz drug substance and efavirenz L- and S-SNEDDS based on other marketed (co)polymers (b) (after three months of storage at 30 °C/65% RH) in 500 mL 0.1 M HCl in USP apparatus II. Each value designates the mean ± S.D. (n = 3).



(a)



(b)

Figure S9. Dissolution profiles of fenofibrate drug substance and fenofibrate L- and S-SNEDDS based on ModE (a), as well as fenofibrate drug substance and fenofibrate L- and S-SNEDDS based on other marketed (co)polymers (b) (after three months of storage at 30 °C/65% RH) in 500 mL 0.1 M HCl in USP apparatus II. Each value designates the mean ± S.D. (n = 3).